Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.02 USD | +0.29% | -4.19% | -13.82% |
05-03 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
05-02 | Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.82% | 3.4B | |
+5.25% | 109B | |
+11.37% | 105B | |
-0.38% | 22.25B | |
-11.98% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.16% | 13.76B | |
+36.50% | 12.46B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Wells Fargo Initiates Ultragenyx Pharmaceutical With Overweight Rating, Price Target is $72